Alvotech Sets Sights On Stelara Submission By Close Of 2022
Company In Strong Position To Capitalize On Ustekinumab Opportunity
Executive Summary
Tipped to bring in revenues from its proposed Stelara biosimilar of $600m in 2027, Alvotech has confirmed plans for a potentially landmark filing with major regulators by the end of the year.